SLC5A2 and endothelial dysfunction: The use of SGLT2 inhibitors leads to an increase in serum magnesium levels, an improvement in endothelial dysfunction, a reduction in arterial stiffness, and decreased resistance in the arterial circulation of the renal graft [39].